Vascular risk factors and Alzheimer’s disease

References

• Hachinski V, Munoz D. Vascular factors in cognitive impairment – where are we now? Ann. NY Acad. Sci.903, 1–5 (2000).
   PubMed Web of Science ®Google Scholar
• Skoog I, Lernfelt B, Landahl S et al. 15-year longitudinal study of blood pressure and dementia. Lancet347, 1141–1145 (1996).
   PubMed Web of Science ®Google Scholar
• Leibson CL, Rocca WA, Hanson VA et al. Risk of dementia among persons with diabetes mellitus: a population-based cohort study. Am. J. Epidemiol.145, 301–308 (1997).
   PubMed Web of Science ®Google Scholar
• Ott BR. Cognition and behavior in patients with Alzheimer’s disease. J. Gend. Specif. Med.2, 63–69 (1999).
   PubMedGoogle Scholar
• Harris Y, Gorelick PB, Freels S, Billingsley M, Brown N, Robinson D. Neuroepidemiology of vascular and Alzheimer’s dementia among African–American women. J. Natl Med. Assoc.87, 741–745 (1995).
   PubMedGoogle Scholar
• Mortel KF, Wood S, Pavol MA, Meyer JS, Rexer JL. Analysis of familial and individual risk factors among patients with ischemic vascular dementia and Alzheimer’s disease. Angiology44, 599–605 (1993).
   PubMed Web of Science ®Google Scholar
• Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, Breteler MM. Diabetes mellitus and the risk of dementia: the Rotterdam Study. Neurology53, 1937–1942 (1999).
   PubMed Web of Science ®Google Scholar
• Hofman A, Ott A, Breteler MM et al. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer’s disease in the Rotterdam Study. Lancet349, 151–154 (1997).
   PubMed Web of Science ®Google Scholar
• Launer LJ, White LR, Petrovitch H, Ross GW, Curb JD. Cholesterol and neuropathologic markers of AD: a population-based autopsy study. Neurology59, 788–789 (2002).
   PubMedGoogle Scholar
• Ott A, Breteler MM, deBruyne MC, van Harskamp F, Grobbee DE, Hofman A. Atrial fibrillation and dementia in a population-based study. The Rotterdam Study. Stroke28(2), 316–321 (1997).
   PubMed Web of Science ®Google Scholar
• Kilander L, Andren B, Nyman H, Lind L, Boberg M, Lithell H. Atrial fibrillation is an independent determinant of low cognitive function: a cross-sectional study in elderly men. Stroke29, 1816–1820 (1998).
   PubMed Web of Science ®Google Scholar
• Ott BR, Grace J. Vascular dementia. Med. Health R.I.80, 150–154 (1997).
   PubMedGoogle Scholar
• Petrovitch HL, White LR, Izmirilian G et al. Midlife blood pressure and neuritic plaques, neurofibrillary tangles, and brain weight at death: the HAAS. Honolulu-Asia aging Study. Neurobiol. Aging21, 57–62 (2000).
   PubMed Web of Science ®Google Scholar
• Kivipelto M, Helkala EL, Hanninen T et al. Midlife vascular risk factors and late-life mild cognitive impairment: a population-based study. Neurology56, 1683–1689 (2001).
   PubMed Web of Science ®Google Scholar
• Kivipelto M, Helkala EL, Laakso MP et al. Midlife vascular risk factors and Alzheimer’s disease in later life: longitudinal, population based study. Br. Med. J.322(7300), 1447–1451 (2001).
   PubMed Web of Science ®Google Scholar
• Launer LJ, Masaki K, Petrovitch H, Foley D, Havlik RJ. The association between midlife blood pressure levels and late-life cognitive function. The Honolulu–Asia Aging Study. JAMA274, 1846–1851 (1995).
   PubMed Web of Science ®Google Scholar
• Tan ZS, Seshadri S, Beiser A et al. Plasma total cholesterol level as a risk factor for Alzheimer disease: the Framingham Study. Arch. Intern. Med.163, 1053–1057 (2003).
   PubMed Web of Science ®Google Scholar
• Olichney JM, Hansen LA, Lee JH, Hofstetter CR, Katzman R, Thal LJ. Relationship between severe amyloid angiopathy, apolipoprotein E genotype, and vascular lesions in Alzheimer’s disease. Ann. NY Acad. Sci.903, 138–143 (2000).
   PubMedGoogle Scholar
• Johnston JM, Nazar-Stewart V, Kelsey SF, Kamboh MI, Ganguli M. Relationships between cerebrovascular events, APOE polymorphism and Alzheimer’s disease in a community sample. Neuroepidemiology19, 320–326 (2000).
   PubMedGoogle Scholar
• Skoog I. Vascular aspects in Alzheimer’s disease. J. Neural Transm. Suppl.59, 37–43 (2000).
   PubMedGoogle Scholar
• Dede DS, Yavuz B, Yavuz BB et al. Assessment of endothelial function in Alzheimer’s disease: is Alzheimer’s disease a vascular disease? J. Am. Geriatr. Soc.55, 1613–1617 (2007).
   PubMed Web of Science ®Google Scholar
• Forette F, Seux ML, Staessen JA et al. Prevention of dementia in randomised double-blind placebo-controlled systolic hypertension in Europe (Syst-Eur) trial. Lancet352, 1347–1351 (1998).
   PubMed Web of Science ®Google Scholar
• Forette F, Seux ML, Staessen JA et al. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch. Intern. Med.162, 2046–2052 (2002).
   PubMed Web of Science ®Google Scholar
• Tzourio C, Anderson C, Chapman N et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch. Intern. Med.163, 1069–1075 (2003).
   PubMed Web of Science ®Google Scholar
• Murray MD, Lane KA, Gao S et al. Preservation of cognitive function with antihypertensive medications: a longitudinal analysis of a community-based sample of African Americans. Arch. Intern. Med.162, 2090–2096 (2002).
   PubMed Web of Science ®Google Scholar
• Lithell H, Hansson L, Skoog I et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J. Hypertens.21, 875–886 (2003).
   PubMed Web of Science ®Google Scholar
• Hooijmans CR, Rutters F, Dederen PJ et al. Changes in cerebral blood volume and amyloid pathology in aged Alzheimer APP/PS1 mice on a docosahexaenoic acid (DHA) diet or cholesterol enriched typical western diet (TWD). Neurobiol. Dis.28, 16–29 (2007).
   PubMed Web of Science ®Google Scholar
• Wang J, Ho L, Chen L et al. Valsartan lowers brain β-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease. J. Clin. Invest.117, 3393–3402 (2007).
   PubMed Web of Science ®Google Scholar
• Sarti C, Pantoni L. Experimental models of vascular dementia: a focus on white matter disease and incomplete infarction. In: Vascular Cognitive Impairment. Bowler JV and Hachinski V (Eds). Oxford University Press, NY, USA 76–92 (2003).
   Google Scholar
• Kalaria RN, Bhatti SU, Palatinsky EA et al. Accumulation of the β amyloid precursor protein at sites of ischemic injury in rat brain. Neuroreport4, 211–214 (1993).
   PubMed Web of Science ®Google Scholar
• Jendroska K, Poewe W, Daniel SE et al. Ischemic stress induces deposition of amyloid b immunoreactivity in human brain. Acta Neuropathol. (Berl.)90(5), 461–466 (1995).
   PubMed Web of Science ®Google Scholar
• Jendroska K, Hoffmann OM, Patt S. Amyloid b peptide and precursor protein (APP) in mild and severe brain ischemia. Ann. NY Acad. Sci.826, 401–405 (1997).
   PubMedGoogle Scholar
• Grilli M, Diodato E, Lozza G et al. Presenilin-1 regulates the neuronal threshold to excitotoxicity both physiologically and pathologically. Proc. Natl Acad. Sci. USA97, 12822–12827 (2000).
   PubMedGoogle Scholar
• Mattson MP, Zhu H, Yu J, Kindy MS. Presenilin-1 mutation increases neuronal vulnerability to focal ischemia in vivo and to hypoxia and glucose deprivation in cell culture: involvement of perturbed calcium homeostasis. J. Neurosci.20, 1358–1364 (2000).
   PubMed Web of Science ®Google Scholar
• Zhang F, Eckman C, Younkin S, Hsiao KK, Iadecola C. Increased susceptibility to ischemic brain damage in transgenic mice overexpressing the amyloid precursor protein. J. Neurosci.17(20), 7655–7661 (1997).
   PubMed Web of Science ®Google Scholar
• Whitehead SN, Hachinski VC, Cechetto DF. Interaction between a rat model of cerebral ischemia and β-amyloid toxicity: I. Inflammatory responses. Stroke36, 107–112 (2005).
   PubMed Web of Science ®Google Scholar
• Whitehead SN, Cheng G, Hachinski VC, Cechetto DF. Interaction between a rat model of cerebral ischemia and β-amyloid toxicity: II. Effects of triflusal. Stroke36(8), 1782–1789 (2005).
   PubMedGoogle Scholar
• Whitehead SN, Cheng G, Hachinski VC, Cechetto DF. Progressive increase in infarct size, neuroinflammation, and cognitive deficits in the presence of high levels of amyloid. Stroke38, 3245–3250 (2007).
   PubMedGoogle Scholar
• Grammas P, Yamada M, Zlokovic B. The cerebromicrovasculature: a key player in the pathogenesis of Alzheimer’s disease. J. Alzheimers Dis.4, 217–223 (2002).
   PubMed Web of Science ®Google Scholar
• de la Torre JC. Vascular basis of Alzheimer’s pathogenesis. Ann. NY Acad. Sci.977, 196–215 (2002).
   PubMed Web of Science ®Google Scholar
• Kalaria R. Similarities between Alzheimer’s disease and vascular dementia. J. Neurol. Sci.203–204, 29–34 (2002).
   PubMed Web of Science ®Google Scholar
• Aliev G, Seyidova D, Neal ML et al. Atherosclerotic lesions and mitochondria DNA deletions in brain microvessels as a central target for the development of human AD and AD-like pathology in aged transgenic mice. Ann. NY Acad. Sci.977, 45–64 (2002).
   PubMed Web of Science ®Google Scholar
• Zlokovic BV. Vascular disorder in Alzheimer’s disease: role in pathogenesis of dementia and therapeutic targets. Adv. Drug Deliv. Rev.54, 1553–1559 (2002).
   PubMedGoogle Scholar
• Pluta R, Misicka A, Barcikowska M, Spisacka S, Lipkowski AW, Januszewski S. Possible reverse transport of β-amyloid peptide across the blood-brain barrier. Acta Neurochir. Suppl.76, 73–77 (2000).
   PubMedGoogle Scholar
• Rhodin JA, Thomas T. A vascular connection to Alzheimer’s disease. Microcirculation8, 207–220 (2001).
   PubMed Web of Science ®Google Scholar
• Giri R, Selvaraj S, Miller CA et al. Effect of endothelial cell polarity on β-amyloid-induced migration of monocytes across normal and AD endothelium. Am. J. Physiol. Cell Physiol.283, C895-C904 (2002).
   Google Scholar
• MacIntyre A, Hammond CJ, Little CS, Appelt DM, Balin BJ. Chlamydia pneumoniae infection alters the junctional complex proteins of human brain microvascular endothelial cells. FEMS Microbiol. Lett.217, 167–172 (2002).
   PubMedGoogle Scholar
• MacIntyre A, Abramov R, Hammond CJ et al.Chlamydia pneumoniae infection promotes the transmigration of monocytes through human brain endothelial cells. J. Neurosci. Res.71, 740–750 (2003).
   PubMed Web of Science ®Google Scholar
• Kalaria RN. Linking cerebrovascular defense mechanisms in brain ageing and Alzheimer’s disease. Neurobiol. Aging (2008) (Epub ahead of print).
   Google Scholar
• Zhang X, Zhou K, Wang R et al. Hypoxia-inducible factor 1α (HIF-1α)-mediated hypoxia increases BACE1 expression and β-amyloid generation. J. Biol. Chem.282, 10873–10880 (2007).
   PubMed Web of Science ®Google Scholar
• van Dijk EJ, Prins ND, Hofman A, van Duijn CM, Koudstaal PJ, Breteler MM. Plasma β amyloid and impaired CO2-induced cerebral vasomotor reactivity. Neurobiol. Aging28, 707–712 (2007).
   PubMedGoogle Scholar
• Sun X, He G, Qing H et al. Hypoxia facilitates Alzheimer’s disease pathogenesis by up-regulating BACE1 gene expression. Proc. Natl Acad. Sci. USA103, 8727–8732 (2006).
   PubMedGoogle Scholar
• Arvin B, Neville LF, Barone FC, Feuerstein GZ. The role of inflammation and cytokines in brain injury. Neurosci. Biobehav. Rev.20(3), 445–452 (1996).
   PubMed Web of Science ®Google Scholar
• Nogawa S, Zhang F, Ross ME, Iadecola C. Cyclo-oxygenase-2 gene expression in neurons contributes to ischemic brain damage. J. Neurosci.17(8), 2746–2755 (1997).
   PubMed Web of Science ®Google Scholar
• Stoll G, Jander S, Schroeter M. Inflammation and glial responses in ischemic brain lesions. Prog. Neurobiol.56(2), 149–171 (1998).
   PubMed Web of Science ®Google Scholar
• Bales KR, Du Y, Holtzman D, Cordell B, Paul SM. Neuroinflammation and Alzheimer’s disease: critical roles for cytokine/Aβ-induced glial activation, NF-κB, and apolipoprotein E. Neurobiol. Aging21, 427–432 (2000).
   PubMed Web of Science ®Google Scholar
• McGeer PL, McGeer EG. The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res. Brain Res. Rev.21(2), 195–218 (1995).
   PubMed Web of Science ®Google Scholar
• McGeer PL, McGeer EG, Yasojima K. Alzheimer disease and neuroinflammation. J. Neural Transm. Suppl.59, 53–57 (2000).
   PubMedGoogle Scholar
• McGeer PL, McGeer EG. Innate immunity, local inflammation, and degenerative disease. Sci. Aging Knowledge Environ.29, RE3 (2002).
   Google Scholar
• Passinetti GM. From epidemiology to therapeutic trials with anti-inflammatory drugs in Alzheimer’s disease: the role of NSAIDs and cyclooxygenase in β-amyloidosis and clinical dementia. J. Alzheimers Dis.4, 435–445 (2002).
   PubMedGoogle Scholar
• Veld BA, Ruitenberg A, Hofman A et al. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer’s disease. N. Engl. J. Med.345, 1515–1521 (2001).
   PubMedGoogle Scholar
• Fernández de Arriba A, Cavalcanti F, Miralles A et al. Inhibition of cyclooxygenase-2 expression by 4-trifluoromethyl derivatives of salicylate, triflusal, and its deacetylated metabolite, 2-hydroxy-4-trifluoromethylbenzoic acid. Mol. Pharmacol.55, 753–760 (1999).
   PubMedGoogle Scholar
• Cheng G, Whitehead SN, Hachinski V, Cechetto DF. Effects of pyrrolidine dithiocarbamate on β-amyloid (25-35)-induced inflammatory responses and memory deficits in the rat. Neurobiol. Dis.23(1), 140–151 (2006).
   PubMedGoogle Scholar
• Ekstrom PA, Tomlinson DR. Impaired nerve regeneration in streptozotocin-diabetic rats is improved by treatment with gangliosides. Exp. Neurol.109, 200–203 (1990).
   PubMed Web of Science ®Google Scholar
• Feldman EL, Stevens MJ, Greene DA. Pathogenesis of diabetic neuropathy. Clin. Neurosci.4, 365–370 (1997).
   PubMedGoogle Scholar
• Greene DA, Stevens MJ, Feldman EL. Diabetic neuropathy: scope of the syndrome. Am. J. Med.107, S2–S8 (1999).
   Google Scholar
• Yorek MA, Wiese TJ, Davidson EP et al. Reduced motor nerve conduction velocity and Na+-K+-ATPase activity in rats maintained on L-fucose diet. Reversal by myo-inositol supplementation. Diabetes42, 1401–1406 (1993).
   PubMedGoogle Scholar
• Biessels GJ, Kappelle AC, Bravenboer B, Erkelens DW, Gispen WH. Cerebral function in diabetes mellitus. Diabetologia37, 643–650 (1994).
   PubMed Web of Science ®Google Scholar
• McCall AL. The impact of diabetes on the CNS. Diabetes41, 557–570 (1992).
   PubMed Web of Science ®Google Scholar
• Asplund K, Hagg E, Helmers C, Lithner F, Strand T, Wester PO. The natural history of stroke in diabetic patients. Acta Med. Scand.207, 417–424 (1980).
   PubMedGoogle Scholar
• Stewart R, Liolitsa D. Type 2 diabetes mellitus, cognitive impairment and dementia. Diabet. Med.16, 93–112 (1999).
   PubMed Web of Science ®Google Scholar
• Auer RN, Wieloch T, Olsson Y, Siesjo BK. The distribution of hypoglycemic brain damage. Acta Neuropathol. (Berl.)64, 177–191 (1984).
   PubMed Web of Science ®Google Scholar
• Auer R, Kalimo H, Olsson Y, Wieloch T. The dentate gyrus in hypoglycemia: pathology implicating excitotoxin-mediated neuronal necrosis. Acta Neuropathol. (Berl.)67, 279–288 (1985).
   PubMedGoogle Scholar
• Kramer L, Fasching P, Madl C et al. Previous episodes of hypoglycemic coma are not associated with permanent cognitive brain dysfunction in IDDM patients on intensive insulin treatment. Diabetes47, 1909–1914 (1998).
   PubMed Web of Science ®Google Scholar
• Schoenle EJ, Schoenle D, Molinari L, Largo RH. Impaired intellectual development in children with Type I diabetes: association with HbA(1c), age at diagnosis and sex. Diabetologia45, 108–114 (2002).
   PubMed Web of Science ®Google Scholar
• Russell JW, Sullivan KA, Windebank AJ, Herrmann DN, Feldman EL. Neurons undergo apoptosis in animal and cell culture models of diabetes. Neurobiol.Dis.6, 347–363 (1999).
   PubMed Web of Science ®Google Scholar
• Bertrand F, Atfi A, Cadoret A et al. A role for nuclear factor κB in the antiapoptotic function of insulin. J. Biol. Chem.273, 2931–2938 (1998).
   PubMedGoogle Scholar
• Lee-Kwon W, Park D, Baskar PV, Kole S, Bernier M. Antiapoptotic signaling by the insulin receptor in Chinese hamster ovary cells. Biochemistry37, 15747–15757 (1998).
   PubMed Web of Science ®Google Scholar
• Russell JW, Feldman EL. Insulin-like growth factor-I prevents apoptosis in sympathetic neurons exposed to high glucose. Horm. Metab. Res.31(2–3), 90–106 (1999).
   PubMed Web of Science ®Google Scholar
• Russell JW, Windebank AJ, Schenone A, Feldman EL. Insulin-like growth factor-I prevents apoptosis in neurons after nerve growth factor withdrawal. J. Neurobiol.36, 455–467 (1998).
   PubMedGoogle Scholar
• Singleton JR, Randolph AE, Feldman EL. Insulin-like growth factor I receptor prevents apoptosis and enhances neuroblastoma tumorigenesis. Cancer Res.56, 4522–4529 (1996).
   PubMed Web of Science ®Google Scholar
• Fernyhough P, Diemel LT, Brewster WJ, Tomlinson DR. Altered neurotrophin mRNA levels in peripheral nerve and skeletal muscle of experimentally diabetic rats. J. Neurochem.64, 1231–1237 (1995).
   PubMed Web of Science ®Google Scholar
• Hanaoka Y, Ohi T, Furukawa S, Furukawa Y, Hayashi K, Matsukura S. Effect of 4-methylcatechol on sciatic nerve growth factor level and motor nerve conduction velocity in experimental diabetic neuropathic process in rats. Exp. Neurol.115, 292–296 (1992).
   PubMedGoogle Scholar
• Hanaoka Y, Ohi T, Furukawa S, Furukawa Y, Hayashi K, Matsukura S. The therapeutic effects of 4-methylcatechol, a stimulator of endogenous nerve growth factor synthesis, on experimental diabetic neuropathy in rats. J. Neurol. Sci.122, 28–32 (1994).
   PubMedGoogle Scholar
• Rodriguez-Pena A, Botana M, Gonzalez M, Requejo F. Expression of neurotrophins and their receptors in sciatic nerve of experimentally diabetic rats. Neurosci. Lett.200, 37–40 (1995).
   PubMed Web of Science ®Google Scholar
• Tomlinson DR, Fernyhough P, Diemel LT. Role of neurotrophins in diabetic neuropathy and treatment with nerve growth factors. Diabetes46(Suppl. 2), S43–S49 (1997).
   Web of Science ®Google Scholar
• McCall AL, Millington WR, Wurtman RJ. Metabolic fuel and amino acid transport into the brain in experimental diabetes mellitus. Proc. Natl Acad. Sci. USA79, 5406–5410 (1982).
   PubMedGoogle Scholar
• McCall AL, Gould JB, Ruderman NB. Diabetes-induced alterations of glucose metabolism in rat cerebral microvessels. Am. J. Physiol.247, E462–E467 (1984).
   Google Scholar
• Reagan LP, Magariños AM, Lucas LR, van Bueren A, McCall AL, McEwen BS. Regulation of GLUT-3 glucose transporter in the hippocampus of diabetic rats subjected to stress. Am. J. Physiol.276(5 Pt 1), E879–E886 (1999).
   Google Scholar
• Reagan LP, Magariños AM, Yee DK et al. Oxidative stress and HNE conjugation of GLUT3 are increased in the hippocampus of diabetic rats subjected to stress. Brain Res.862(1–2), 292–300 (2000).
   PubMed Web of Science ®Google Scholar
• Figlewicz DP, Brot MD, McCall AL, Szot P. Diabetes causes differential changes in CNS noradrenergic and dopaminergic neurons in the rat: a molecular study. Brain Res.736, 54–60 (1996).
   PubMed Web of Science ®Google Scholar
• Li ZG, Zhang W, Grunberger G, Sima AA. Hippocampal neuronal apoptosis in type 1 diabetes. Brain Res.946, 221–231 (2002).
   PubMed Web of Science ®Google Scholar
• Biessels GJ, Stevens EJ, Mahmood SJ, Gispen WH, Tomlinson DR. Insulin partially reverses deficits in peripheral nerve blood flow and conduction in experimental diabetes. J. Neurol. Sci.140(1–2), 12–20 (1996). Erratum in: J. Neurol. Sci.144(1–2), 234 (1996).
   PubMedGoogle Scholar
• Lupien SB, Bluhm EJ, Ishii DN. Systemic insulin-like growth factor-I administration prevents cognitive impairment in diabetic rats, and brain IGF regulates learning/memory in normal adult rats. J. Neurosci. Res.74(4), 512–523 (2003).
   PubMed Web of Science ®Google Scholar
• Popovic M, Biessels GJ, Isaacson RL, Gispen WH. Learning and memory in streptozotocin-induced diabetes rats in a novel spatial/object discrimination task. Behav. Brain Res.122(2), 201–207 (2001).
   PubMed Web of Science ®Google Scholar
• Nitta A, Murai R, Suzuki N et al. Diabetic neuropathies in brain are induced by deficiency of BDNF. Neurotoxicol. Teratol.24, 695–701 (2002).
   PubMed Web of Science ®Google Scholar
• Ubeda M, Rukstalis JM, Habener JF. Inhibition of cyclin-dependent kinase 5 activity protects pancreatic β cells from glucotoxicity. J. Biol. Chem.281, 28858–28864 (2006).
   PubMed Web of Science ®Google Scholar
• Ho L, Qin W, Pompl PN et al. Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer’s disease. FASEB J.18, 902–904 (2004).
   PubMed Web of Science ®Google Scholar
• Matsuoka Y, Picciano M, Malester B et al. Inflammatory responses to amyloidosis in a transgenic mouse model of Alzheimer’s disease. Am. J. Pathol.158, 1345–1354 (2001).
   PubMed Web of Science ®Google Scholar
• Abramov AY, Canevari L, Duchen MR. Changes in intracellular calcium and glutathione in astrocytes as the primary mechanism of amyloid neurotoxicity. J. Neurosci.23, 5088–5095 (2003).
   PubMed Web of Science ®Google Scholar
• Danton GH, Dietrich WD. Inflammatory mechanisms after ischemia and stroke. J. Neuropathol. Exp. Neurol.62, 127–136 (2003).
   PubMed Web of Science ®Google Scholar